Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells.
Given that prolonged exposure to unopposed estrogen has been implicated in endometrial carcinogenesis, our goal was to evaluate the effect of As(2)O(3) on regulation of estrogen receptor-alpha (ERa) expression in endometrial cancer cells. As(2)O(3) inhibited ER- mRNA and protein expression in a dose-dependent manner in both the Ishikawa and ECC-1 endometrial cancer cell lines. Treatment with As(2)O(3) resulted in rapid phosphorylation of the p42/p44 MAPK which could be abolished by addition of the MAPK inhibitor, U0126. Although treatment with U0126 alone resulted in up-regulation of ER- mRNA and protein, exposure to U0126 in combination with As(2)O(3) counteracted As(2)O(3)'s inhibitory effect on ER- expression. We provide evidence that As(2)O(3) inhibits ER- mRNA and protein expression in endometrial cancer cells, potentially through interaction with the MAPK pathway. Thus, As(2)O(3) may be valuable for its anti-estrogenic activity in combination with its anti-tumorigenic effects and be a novel therapeutic agent for endometrial cancer.
Bae-Jump
Victoria L
VL
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina 27599, USA. vbae@unch.unc.edu
Zhou
Chunxiao
C
Boggess
John F
JF
Gehrig
Paola A
PA
D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects* / Q000502:physiology; D020928:Mitogen-Activated Protein Kinases / Q000502:physiology; D010087:Oxides / Q000494:pharmacology* / Q000627:therapeutic use
D001152:Arsenicals; D047628:Estrogen Receptor alpha; D010087:Oxides; D020928:Mitogen-Activated Protein Kinases; D000077237:Arsenic Trioxide